VKTX241129C55000
- 0.50
- -0.06-10.71%
Viking Therapeutics Newsroom
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Viking Therapeutics Analyst Ratings
B.Riley Financial Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $109
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Raises Target Price to $164
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Viking Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Viking Therapeutics, Raises Price Target to $102
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $118
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Viking Therapeutics (VKTX) Gets a Buy From Truist Financial
Promising Phase 1 Results for Viking Therapeutics' VK2735: Analyst Recommends Buy Rating
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $125
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $138
Analysts Offer Insights on Healthcare Companies: Community Health (CYH), Viking Therapeutics (VKTX) and Boston Scientific (BSX)
Viking Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138